TWiV 1004: Clinical update with Dr. Daniel Griffin

In his weekly clinical update, Dr. Griffin discusses the U.S. Food and Drug Administration approving Arexvy: the first respiratory syncytial virus (RSV) vaccine approved for use in the United State, association between SARS-CoV-2 and metagenomic content of samples from the Huanan Seafood Market, researchers disagree over how bad it is to be reinfected and whether COVID-19 can cause lasting changes to the immune system, virtual care and emergency department use during the COVID-19 pandemic among patients of family physicians in Canada, vaccination with BCG-Denmark did not result in a lower risk of COVID-19 among health care workers than placebo, NVX-CoV2373 vaccine efficacy against hospitalization, comparative effectiveness of the SARS-COV-2 vaccines during Delta dominance, assessment of gender-specific COVID-19 case fatality risk per malignant neoplasm type, clinical outcomes following treatment for COVID-19 with Nirmatrelvir/Ritonavir and Molnupiravir among patients living in nursing homes, timing of intubation and ICU mortality in COVID-19 patients, real-life experience with Remdesivir for treatment of COVID-19 among older adults, and how long COVID brain fog and muscle pain are associated with longer time to clearance of SARS-CoV-2 RNA from the upper respiratory tract during acute infection. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode FDA approves Arexvy, the first RSV vaccine approved in the US (FDA) Association between SARS-CoV-2 and content of samples from the Huanan Seafood Market (bioRxiv) Researchers disagree over how bad it is to be reinfected with COVID-19 and lasting changes to the immune system (Nature) Virtual care and emergency department use during the COVID-19 Pandemic among patients of family physicians (JAMA) Vaccination with BCG-Denmark did not result in a lower risk of COVID-19 among health care workers (NEJM) NVX-CoV2373 vaccine efficacy against hospitalization (Vaccine) Comparative effectiveness of the SARS-COV-2 vaccines during Delta (Cell) Assessment of gender-specific COVID-19 case fatality risk (JAMA) Clinical outcomes following treatment for COVID-19 with Nirmatrelvir/Ritonavir and Molnupiravir (JAMA) Timing of intubation and ICU mortality in COVID-19 patients (BMC) Real-life experience with Remdesivir for treatment of COVID-19 (JAC) Long COVID brain fog and muscle pain are associated with longer time to clearance of SARS-CoV-2 RNA (Frontiers) Contribute to our FIMRC fundraiser at PWB Letters read on TWiV 1004 Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]